249 related articles for article (PubMed ID: 12733725)
1. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.
Garnero P; Ferreras M; Karsdal MA; Nicamhlaoibh R; Risteli J; Borel O; Qvist P; Delmas PD; Foged NT; Delaissé JM
J Bone Miner Res; 2003 May; 18(5):859-67. PubMed ID: 12733725
[TBL] [Abstract][Full Text] [Related]
2. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
3. Regulation and enzymatic basis of bone resorption by human osteoclasts.
Fuller K; Kirstein B; Chambers TJ
Clin Sci (Lond); 2007 Jun; 112(11):567-75. PubMed ID: 17241109
[TBL] [Abstract][Full Text] [Related]
4. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K.
Sassi ML; Eriksen H; Risteli L; Niemi S; Mansell J; Gowen M; Risteli J
Bone; 2000 Apr; 26(4):367-73. PubMed ID: 10719280
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities.
Delaissé JM; Andersen TL; Engsig MT; Henriksen K; Troen T; Blavier L
Microsc Res Tech; 2003 Aug; 61(6):504-13. PubMed ID: 12879418
[TBL] [Abstract][Full Text] [Related]
6. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
7. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation.
Charni-Ben Tabassi N; Desmarais S; Bay-Jensen AC; Delaissé JM; Percival MD; Garnero P
Osteoarthritis Cartilage; 2008 Oct; 16(10):1183-91. PubMed ID: 18403221
[TBL] [Abstract][Full Text] [Related]
8. Can quaternary ammonium methacrylates inhibit matrix MMPs and cathepsins?
Tezvergil-Mutluay A; Agee KA; Mazzoni A; Carvalho RM; Carrilho M; Tersariol IL; Nascimento FD; Imazato S; Tjäderhane L; Breschi L; Tay FR; Pashley DH
Dent Mater; 2015 Feb; 31(2):e25-32. PubMed ID: 25467953
[TBL] [Abstract][Full Text] [Related]
9. Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases.
Parikka V; Väänänen A; Risteli J; Salo T; Sorsa T; Väänänen HK; Lehenkari P
Matrix Biol; 2005 Sep; 24(6):438-47. PubMed ID: 16098718
[TBL] [Abstract][Full Text] [Related]
10. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.
Eriksen EF; Charles P; Melsen F; Mosekilde L; Risteli L; Risteli J
J Bone Miner Res; 1993 Feb; 8(2):127-32. PubMed ID: 8442431
[TBL] [Abstract][Full Text] [Related]
11. Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation.
Nishi Y; Atley L; Eyre DE; Edelson JG; Superti-Furga A; Yasuda T; Desnick RJ; Gelb BD
J Bone Miner Res; 1999 Nov; 14(11):1902-8. PubMed ID: 10571690
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
13. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation.
Sondergaard BC; Henriksen K; Wulf H; Oestergaard S; Schurigt U; Bräuer R; Danielsen I; Christiansen C; Qvist P; Karsdal MA
Osteoarthritis Cartilage; 2006 Aug; 14(8):738-48. PubMed ID: 16563811
[TBL] [Abstract][Full Text] [Related]
14. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula.
Shorey S; Heersche JN; Manolson MF
Bone; 2004 Oct; 35(4):909-17. PubMed ID: 15454098
[TBL] [Abstract][Full Text] [Related]
15. Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts.
Parikka V; Lehenkari P; Sassi ML; Halleen J; Risteli J; Härkönen P; Väänänen HK
Endocrinology; 2001 Dec; 142(12):5371-8. PubMed ID: 11713237
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
18. Serum osteocalcin and CTX-MMP concentration in young exercising thoroughbred racehorses.
Carstanjen B; Amory H; Sulon J; Hars O; Remy B; Langlois P; Lepage OM
J Vet Med A Physiol Pathol Clin Med; 2005 Apr; 52(3):114-20. PubMed ID: 15836441
[TBL] [Abstract][Full Text] [Related]
19. Release of ICTP and CTX telopeptides from demineralized dentin matrices: Effect of time, mass and surface area.
Turco G; Cadenaro M; Maravić T; Frassetto A; Marsich E; Mazzoni A; Di Lenarda R; Tay FR; Pashley DH; Breschi L
Dent Mater; 2018 Mar; 34(3):452-459. PubMed ID: 29301651
[TBL] [Abstract][Full Text] [Related]
20. Erosive arthritis in a patient with pycnodysostosis: an experiment of nature.
Ainola M; Valleala H; Nykänen P; Risteli J; Hanemaaijer R; Konttinen YT
Arthritis Rheum; 2008 Nov; 58(11):3394-401. PubMed ID: 18975331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
